Phenylpiracetam crystal rocks

Phenylpiracetam crystal rocks – More information

Phenylpiracetam (also known as Phenotropil and Carphedon) is a central nervous system stimulant and nootropic agent belonging to the racetam family of drugs. Although it is one of the first derivatives of piracetam to be synthesized and documented, research into its properties and efficacy in humans is limited.

Phenylpiracetam is readily available and sold through online vendors as a dietary supplement in the United States. Dosages are commonly reported to be around nearly twelve times those of noopept, making it less potent while offering comparable benefit.

Supplementation of phenylpiracetam tends to be in the dosage range of 100 – 300 mg taken over the course of a day, either in two to three evenly spread dosing periods (such as three doses of 100mg or 200mg).

Phenylpiracetam has protected against scopolamine-induced amnesia both in rat populations, suggesting it can aid recovery from deliriant intoxication and other typically cognitively impaired states by preserving adequate levels of acetylcholine as a primary mechanism.

Many people report that phenylpiracetam effects (especially stimulation) are more pronounced than other racetams. That may be due phenypiracetam’s action as a dopamine reuptake inhibitor and noradrenaline reuptake inhibitor.

clinical data

Phenylpiracetam dosage table

Phenylpiracetam effect progress

Chemistry

Phenylpiracetam is based on the piracetam molecular skeleton with an additional phenyl group attached to the pyrrolidone nucleus, albeit at a different steric location than the substituted phenyl groups observed on aniracetam or nefiracetam. Due to the chiral center at the fourth position of the pyrrolidinone ring, it can exist in an S or R-isomer; the clinically used form is the racemic mixture.

Toxicity

Several studies suggest that this substance is safe even when high doses are consumed for a long period of time although it is worth noting that the exact toxic dosage is unknown. Anecdotal evidence from those within the community who have tried phenylpiracetam suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed).

It is strongly recommended that one use harm reduction practices when using this drug.

Lethal dosage

The median lethal dosage (LD₅₀) of phenylpiracetam has not been officially published as it has low abuse potential, but is not known to be harmful when exceeding the recommended dosage range.

Tolerance

The chronic use of phenylpiracetam can be considered as non-addictive with a low potential for abuse. It does not seem to be capable of causing psychological dependence among users, although this fact has not been corroborated by clinical studies.
Tolerance to many of the effects of phenylpiracetam develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 – 7 days for the tolerance to be reduced to half and 1 – 2 weeks to be back at baseline (in the absence of further consumption). Phenylpiracetam may presents cross-tolerance with all racetam nootropics, meaning that after the consumption of phenylpiracetam certain nootropics such as aniracetam and piracetam may have a reduced effect.

Legality

Phenylpiracetam, being a member of the racetam family, currently is legally available to buy and sell in most countries, but may still vary by region.